Congratulations to our portfolio company, Reunion Neuroscience, on the announcement of their $103M Series A Financing co-led by Novo Holdings! In August 2023, MPM BioImpact acquired Reunion Neuroscience. As part of our portfolio, Reunion Neuroscience is continuing their mission of developing the next-generation of therapeutics for underserved mental health disorders.
Today, Reunion Neuroscience announced the closing of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings. The financing will support the RECONNECT Phase 2 clinical trial for RE104 in #postpartumdepression and expansion into other psychiatric indications of high unmet need, including adjustment disorder in #cancer. RE104 is a proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders. Read the press release: https://bit.ly/3Wj5fyF
